Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II

• Egile Nagusiak: Julia G. Levina (Egilea), Nato D. Vashakmadze (Egilea), Leyla S. Namazova-Baranova (Egilea), Elena A. Vishneva (Egilea), Mariya S. Karaseva (Egilea), Natalia V. Zhurkova (Egilea), Kamilla E. Efendieva (Egilea), Anna A. Alekseeva (Egilea), Vera G. Kalugina (Egilea), Artur V. Zaz'yan (Egilea)
• Formatua: Liburua
• Argitaratua: Union of pediatricians of Russia, 2022-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background. Enzyme replacement therapy (ERT) with iduronate-2-sulfatase recombinant forms (idursulfase and idursulfase beta) is effective for the management of mucopolysaccharidosis type II (MPS II). Patients with Hunter syndrome require lifelong ERT that can negate endogenous enzyme deficiency. How...